3 Pharma Stocks to Dump Before the Damage Is Done

InvestorPlace2023-10-08

These pharma stocks are likely to cause continued damage to shareholders. Axcella Health (AXLA): AXLA shares are very dangerous right now. Novavax (NVAX): Novavax’s trajectory is what it is. Mind ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2373530079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-08 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2373530079","market":"us","top_or_hot":-1,"title":"3 Pharma Stocks to Dump Before the Damage Is Done","media":"InvestorPlace","content":"<div>\n<p>These pharma stocks are likely to cause continued damage to shareholders. \nAxcella Health (AXLA): AXLA shares are very dangerous right now. \nNovavax (NVAX): Novavax’s trajectory is what it is. \nMind ...</p>\n\n<a href=\"https://investorplace.com/2023/10/3-pharma-stocks-to-dump-before-the-damage-is-done/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks to Dump Before the Damage Is Done</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks to Dump Before the Damage Is Done\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-08 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/10/3-pharma-stocks-to-dump-before-the-damage-is-done/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These pharma stocks are likely to cause continued damage to shareholders. \nAxcella Health (AXLA): AXLA shares are very dangerous right now. \nNovavax (NVAX): Novavax’s trajectory is what it is. \nMind ...</p>\n\n<a href=\"https://investorplace.com/2023/10/3-pharma-stocks-to-dump-before-the-damage-is-done/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0792757196.USD","symbol_name":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","start_time":0,"source_url":"https://investorplace.com/2023/10/3-pharma-stocks-to-dump-before-the-damage-is-done/","article_id":"2373530079","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2373530079","pubTimestamp":1696766448,"columns":[],"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"There's never a shortage of pharma stocks to sell due to the nature of the sector, especially when compounded by current fears.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","TQQQ":"纳指三倍做多ETF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","QID":"纳指两倍做空ETF","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","MNMD":"Mind Medicine (MindMed) Inc.","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU1261432733.SGD":"Fidelity World A-ACC-SGD","AXLA":"Axcella Health Inc.",".IXIC":"NASDAQ Composite","QQQ":"纳指100ETF","LU0058720904.USD":"联博国际健康护理基金A","BK4139":"生物科技","SQQQ":"纳指三倍做空ETF","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","PFE":"辉瑞","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4559":"巴菲特持仓","BK4501":"段永平概念","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","SG9999001176.USD":"United Global Healthcare Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","MRNA":"Moderna, Inc.","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","NVAX":"诺瓦瓦克斯医药","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","BK4551":"寇图资本持仓","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","JNJ":"强生"},"translate_title":"3个制药股在损失发生前抛售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXLA":1,"JNJ":1,"MNMD":1,"MRNA":1,"NVAX":1,"PFE":1,".IXIC":0.79,"TQQQ":0.6,"SQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"These pharma stocks are likely to cause continued damage to shareholders. \nAxcella Health (AXLA): AXLA shares are very dangerous right now. \nNovavax (NVAX): Novavax’s trajectory is what it is. \nMind Medicine (MNMD): MNMD isn’t a short-term play currently.\n\n\n\n\n\n \n\nSource: Sisacorn / Shutterstock.com\n\n\n\nPharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously. It is and will remain a very hit-or-miss sector for investors.\nThat said, it’s important to recognize when business models, future promises of growth and chance of FDA approval are unfavorable. Additionally, the market is showing signs of increased volatility at the moment. That fact is introducing an extra element of risk into these already riskier shares. Some of these firms are truly very close to collapse. Others offer long-term upside that will take a while to materialize — if ever. That said, here are some pharma stocks to sell now.\n\nAxcella Health (AXLA)\nSource: Iryna Imago / Shutterstock.com\nI continue to believe that Axcella Health (NASDAQ:AXLA) is a stock to avoid. In fact, I think it’s one of the more dangerous shares an investor can play with at the moment. I think investors expect the company to produce results in relation to its pursuit of Long Covid treatment commercialization. It exploded recently because fears of a Covid reemergence are high.\nIt also had a patent granted in relation to its business pursuits. However, it isn’t commercialized, and it can’t simply push its pipeline forward any faster than any other pharma firm.\nWhat it did was enact a 1-for-25 reverse stock split that investors have simply ignored. It’s a dangerous stock, to say the least, and I can’t see why investors should expect it to garner sales anytime soon. However, they are treating it as if that is what will happen.\nNever mind that Axcella Health continues to lose money, has suspended research and development and is exactly the kind of biotech that rises and becomes attractive before dramatically declining again.\nNovavax (NVAX)\nSource: pixinoo / Shutterstock.com\nNovavax (NASDAQ:NVAX) will always remain the 1st runner-up in the race to develop a Covid-19 vaccine. That fact has set the stock’s price on a downward trajectory that hasn’t relented. At the height of the vaccine race, its price was close to $300. It now trades for around $7.\nWhile investors may believe in Novavax in relation to Covid boosters, I believe it’s wiser to consider the long-term trajectory of the firm. Novavax is contracting and is expected to continue to do so. Last year’s revenues reached $1.9 billion. However, they’re expected to fall to $1.35 billion this year and $1.28 billion in 2024.\nMy guess is that if demand for boosters gets very high, the established names will fare better than Novavax. In other words, Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ). There’s tons of upside in NVAX shares, and I could certainly be proven wrong here. It could rise and provide quick gains, but I’d rather be safe than sorry in this instance.\nMind Medicine (MNMD)\nSource: Shutterstock\nMind Medicine (NASDAQ:MNMD) isn’t a ticking time bomb in the sense that its stock has legitimate prospects for growth long term. It is developing psychedelics for the treatment of brain disorders. I can’t deny that the growth potential of the sector is real.\nI’ve written about the stock positively in relation to its development of serotonergic psychedelics, including DMT, psilocybin and LSD. Mind Medicine is leveraging the science of neuroplasticity and neuron growth in relation to those compounds. That remains exciting for the long term, and I can’t argue that MNMD has any less potential currently than it did months earlier over the long term. It has a cash runway that is expected to bring it through 2025.\nHowever, I expect trepidation and bearishness from the markets through 2024. Investors are nervous about interest rates and the effects of another rate hike in November. That implies we will see a pivot into safer equities and a more defensive stance overall. That doesn’t favor MNMD. I see investors heading for defensive stocks at the moment. They offer growth, and those wary of conservative plays are probably headed into bonds with their high yields and zero risk.\nOn the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\n\nAlex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2023/10/3-pharma-stocks-to-dump-before-the-damage-is-done/.\n©2023 InvestorPlace Media, LLC\n\n\n\n\nSponsored Headlines","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2373530079"}